ADPT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

59.28M

+24.92%

-0.180

-20.91%

59.30M

+13.07%

-0.172

-14.17%

65.85M

+11.83%

-0.142

-16.66%

Estimates Revision

The market is revising Upward the revenue expectations for Adaptive Biotechnologies Corporation (ADPT) for FY2025, with the revenue forecasts being adjusted by 12.21% over the past three months. During the same period, the stock price has changed by 0.70%.

Revenue Estimates for FY2025

Revise Upward

+12.21%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-30.18%

In Past 3 Month

Stock Price

Go Up

+0.70%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast ADPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADPT is 19.33 USD with a low forecast of 16.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

16.00

Averages

19.33

High

22.00

Current: 0.000

Low

16.00

Averages

19.33

High

22.00

TD Cowen

Buy

maintain

$19 -> $20

2026-01-07

New

Reason

TD Cowen

Price Target

$19 -> $20

2026-01-07

New

maintain

Buy

Reason

TD Cowen raised the firm's price target on Adaptive Biotechnologies to $20 from $19 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.

Morgan Stanley

Tejas Savant

Equal Weight

maintain

$11 -> $16

2025-11-11

Reason

Morgan Stanley

Tejas Savant

Price Target

$11 -> $16

2025-11-11

maintain

Equal Weight

Reason

Morgan Stanley analyst Tejas Savant raised the firm's price target on Adaptive Biotechnologies to $16 from $11 and keeps an Equal Weight rating on the shares following the company's recent Q3 report.

JPMorgan

Rachel Vatnsdal

maintain

$17 -> $20

2025-11-06

Reason

JPMorgan

Rachel Vatnsdal

Price Target

$17 -> $20

2025-11-06

maintain

Reason

JPMorgan analyst Rachel Vatnsdal raised the firm's price target on Adaptive Biotechnologies to $20 from $17 and keeps an Overweight rating on the shares following the Q3 report.

Piper Sandler

Overweight

maintain

$15 -> $20

2025-10-15

Reason

Piper Sandler

Price Target

$15 -> $20

2025-10-15

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Adaptive Biotechnologies to $20 from $15 and keeps an Overweight rating on the shares. The firm notes it surveyed 59 doctors but focused on the 28 who see blood cancers. From its survey, Adaptive continues to stand out as an underappreciated stock in the MRD space, holding the second-highest revenues and volumes specifically linked to minimal residual disease detection, and serving the most covered lives. Piper believes the company has significant growth potential, projecting approximately 30% increases in both volume over the next few years, driven by expanded EMR adoption, recent strategic partnerships, blood-based testing options, and ongoing clinical trials.

Guggenheim

NULL -> Buy

initiated

$20

2025-09-30

Reason

Guggenheim

Price Target

$20

2025-09-30

initiated

NULL -> Buy

Reason

Guggenheim initiated coverage of Adaptive Biotechnologies with a Buy rating and $20 price target.

Guggenheim

initiated

$20

2025-09-30

Reason

Guggenheim

Price Target

$20

2025-09-30

initiated

Reason

Guggenheim initiated coverage of Adaptive Biotechnologies with a Buy rating and $20 price target. The company is and should remain the dominant provider of minimal residual disease blood cancer tests, the analyst tells investors in a research note. The firm sees a path for sustained revenue growth for Adaptive due to continued market conversion, penetration into different indications, and price increases. The shares trade at a \"notable discount\" to other leading cancer specialty lab companies, contends Guggenheim.

Valuation Metrics

The current forward P/E ratio for Adaptive Biotechnologies Corp (ADPT.O) is -25.25, compared to its 5-year average forward P/E of -11.20. For a more detailed relative valuation and DCF analysis to assess Adaptive Biotechnologies Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.20

Current PE

-25.25

Overvalued PE

-2.10

Undervalued PE

-20.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-21.68

Current EV/EBITDA

-108.69

Overvalued EV/EBITDA

5.87

Undervalued EV/EBITDA

-49.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

11.29

Current PS

9.57

Overvalued PS

23.47

Undervalued PS

-0.88

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 176.86% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ADPT News & Events

Events Timeline

No data

News

1.0

2025-12-30Globenewswire

Adaptive Biotechnologies to Present at 44th J.P. Morgan Healthcare Conference

4.5

2025-12-23SeekingAlpha

Adaptive Biotechnologies Leads Life Sciences Tools and Services Stocks in Year-to-Date Performance

8.0

2025-12-19NASDAQ.COM

Options Trading for Adaptive Biotechnologies (ADPT) in the First Week of February 2026

People Also Watch

Frequently Asked Questions

What is Adaptive Biotechnologies Corp (ADPT) stock price today?

The current price of ADPT is 15.76 USD — it has decreased -1.25 % in the last trading day.

What is Adaptive Biotechnologies Corp (ADPT)'s business?

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.

What is the price predicton of ADPT Stock?

What is Adaptive Biotechnologies Corp (ADPT)'s revenue for the last quarter?

Adaptive Biotechnologies Corp revenue for the last quarter amounts to 93.97M USD, increased 102.38 % YoY.

What is Adaptive Biotechnologies Corp (ADPT)'s earnings per share (EPS) for the last quarter?

Adaptive Biotechnologies Corp. EPS for the last quarter amounts to 0.06 USD, decreased -127.27 % YoY.

What changes have occurred in the market's expectations for Adaptive Biotechnologies Corp (ADPT)'s fundamentals?

How many employees does Adaptive Biotechnologies Corp (ADPT). have?

Adaptive Biotechnologies Corp (ADPT) has 619 emplpoyees as of January 10 2026.

What is Adaptive Biotechnologies Corp (ADPT) market cap?

Today ADPT has the market capitalization of 2.41B USD.